Galmed Pharmaceuticals has announced that Professor Ran Oren, M.D., has been named its Chief Medical Officer (CMO).
Dr. Oren will be replacing Dr. Maya Halpern.
"Dr. Oren was a scientific collaborator of our
company's co-founder, the late Professor Tuvia Gilat, and has served as a
member of our Scientific Advisory Board since 2014," Galmed's President
and CEO Allen Baharaff said. "Dr. Oren is a practicing
gastroenterologist and hepatologist and previously was the principal
investigator of Aramchol's Phase IIa study, and we are privileged that he has
agreed to join Galmed and lead the clinical development of Aramchol."
Dr. Oren will continue his commitments at Hebrew University
of Jerusalem as Professor of Gastroenterology & Hepatology, while serving
as Galmed’s CMO.
"I am honored to continue the life work of Professor
Gilat, who was my mentor and friend for many years,” Dr. Oren said. “I
have been scientifically and clinically involved in the field of NAFLD (nonalcoholic fatty liver disease) since
the early 2000s. I view this position at Galmed as an exciting
opportunity for me to contribute to a company that I have been following from
concept to this exciting phase of advanced clinical studies, and I look forward
to working with the Galmed team."
Galmed is a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of liver diseases
Alerts Sign-up